Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CRDL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| CardiolRx | Recurrent Pericarditis | Phase 3 · NCT06708299 | Recruiting |
Also used in these trials (approved or third-party drugs, not CRDL's own candidates): Cannabidiol.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CRDL holds $26.1M in cash and short-term investments and burns about $6M/quarter from operations, an estimated runway of 13 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRDL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| MMCAP International Inc. SPC | Institution (13G, 5%+) | 21,310,099 | 21.26% | 2026-06-30 |
| Tejara Capital Ltd | Institution (13G, 5%+) | 6,382,551 | 6.37% | 2026-09-02 |
| Ikarian Capital, LLC | Institution (13F) | 3,325,000 | 3.32% | 2026-06-30 |
| Boothbay Fund Management, LLC | Institution (13F) | 975,721 | 0.97% | 2026-06-30 |
| Citadel Advisors Llc | Institution (13F) | 796,529 | 0.79% | 2026-06-30 |
| Renaissance Technologies, LLC | Institution (13F) | 772,837 | 0.77% | 2026-06-30 |
| Two Sigma Investments, LP | Institution (13F) | 746,937 | 0.75% | 2026-06-30 |
| Integrity Alliance, Llc. | Institution (13F) | 388,492 | 0.39% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 355,030 | 0.35% | 2026-06-30 |
| Goldman Sachs Group Inc | Institution (13F) | 333,900 | 0.33% | 2026-06-30 |
Share count 100,257,009 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRDL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →